Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease - ScienceDirect
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes - ScienceDirect
PDF) A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson's Disease
Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa | Neuropsychopharmacology
Molecular imaging of levodopa-induced dyskinesias | SpringerLink
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia | Journal of Neurophysiology
The scientific and clinical basis for the treatment of Parkinson disease (2009) | Neurology
Frontiers | Advances in non-dopaminergic treatments for Parkinson's disease
Anxiety: An ignored aspect of Parkinson's disease lacking attention - ScienceDirect
Frontiers | Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia
Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata -
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
Concomitant short‐ and long‐duration response to levodopa in the 6‐OHDA‐lesioned rat: a behavioural and molecular study - Marin - 2007 - European Journal of Neuroscience - Wiley Online Library
PDF) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l‐DOPA treatment and changes in levodopa‐induced dyskinesia - Andersen - 2017 - Journal of Neurochemistry - Wiley Online Library
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts - Espay - 2018 - Annals of Neurology - Wiley Online Library
Frontiers | A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease
Anxiety: An ignored aspect of Parkinson's disease lacking attention - ScienceDirect
Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa | Neuropsychopharmacology
Levodopa pharmacokinetics -from stomach to brain : A study on patients with Parkinson's disease
PDF) A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson's Disease
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson's Disease | Pharmacological Reviews
µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease | Journal of Neuroscience
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson's Disease | Pharmacological Reviews
PDF) A Computational Model of Levodopa-Induced Toxicity in Substantia Nigra Pars Compacta in Parkinson's Disease
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson's Disease | Pharmacological Reviews
l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? - Carta - 2017 - European Journal of Neuroscience - Wiley Online Library
